Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Auris Medical Holding AG (NASDAQ: EARS).

Full DD Report for EARS

You must become a subscriber to view this report.


Recent News from (NASDAQ: EARS)

Today's Research Reports on Trending Tickers: Loxo Oncology and Auris Medical Holding
NEW YORK, NY / ACCESSWIRE / November 2, 2018 / U.S. markets rallied on Thursday, with the S&P 500 Index logging its first 3-day win streak in six weeks, as trade concerns between the U.S. and China continued to ease. The Dow Jones Industrial Average gained 1.06 percent to close at 25,380...
Source: ACCESSWIRE IA
Date: November, 02 2018 08:00
Edison issues initiation on Auris Medical Holding (EARS)
LONDON, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Auris Medical (EARS) is a clinical-stage biopharmaceutical company developing pharmacotherapies for neurologic disorders of the inner ear. The company’s primary focus is on the development of intranasal betahistine for the treatment of acute ...
Source: GlobeNewswire
Date: November, 01 2018 12:00
Auris Medical receives FDA guidance for AM-111 in the treatment of sudden sensorineural hearing loss
Auris Medical Holding AG (NASDAQ: EARS ) announces feedback from a Type C meeting with the FDA related to the development plan and regulatory pathway for AM-111, its investigational treatment for sudden sensorineural hearing loss. More news on: Auris Medical Holding, Healthcare stocks ne...
Source: SeekingAlpha
Date: August, 30 2018 08:41
Auris Medical Receives FDA Guidance at Type C Meeting for AM-111 in the Treatment of Sudden Sensorineural Hearing Loss
Zug, Switzerland, August 30, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental disorders supportive care, announced today feedback from a Type C meeting with the ...
Source: GlobeNewswire
Date: August, 30 2018 08:15
Auris Medical Holding 2018 Q2 - Results - Earnings Call Slides
The following slide deck was published by Auris Medical Holding in conjunction with their 2018 Q2 earnings Read more ...
Source: SeekingAlpha
Date: August, 15 2018 12:22
Auris Medical's (EARS) CEO Thomas Meyer on Q2 2018 Results - Earnings Call Transcript
Auris Medical Holding (EARS) Q2 2018 Earnings Conference Call August 15, 2018 08:00 AM ET Executives Hernan Levett – Chief Financial Officer Thomas Meyer – Chairman and Chief Executive Officer Analysts Juan Serrate – Edison Presentation Operator ...
Source: SeekingAlpha
Date: August, 15 2018 12:13
Auris Medical up 3% premarket on Q2 results
Auris Medical ( EARS ) Q2 results (CHF): Revenues: 0; Net Loss: (3.1M) (+42.6%); Loss Per Share: (0.50) (+59.0%); Quick Assets: 4.4M (-70.7%). More news on: Auris Medical Holding, Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 15 2018 07:44
Auris Medical Reports Second Quarter 2018 Financial Results and Provides Business Update
Dosing in second Phase 1 clinical trial with intranasal betahistine nearing completion Approaching important interactions with regulatory agencies Progressing with strategic repositioning of Company Zug, Switzerland, August 15, 2018 - Auris Medical Holding AG (NASDAQ: EAR...
Source: GlobeNewswire
Date: August, 15 2018 06:45
Auris Medical to Report Second Quarter 2018 Financial Results and Provide Business and Update on Wednesday, August 15, 2018
Zug, Switzerland, August 09, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental health supportive care, today announced that it will provide a business update and ...
Source: GlobeNewswire
Date: August, 09 2018 08:01
Complimentary Technical Snapshots on OHR Pharma and Three More Biotech Stocks
Stock Research Monitor: EARS, NLNK, and OMER LONDON, UK / ACCESSWIRE / July 13, 2018 / If you want a free Stock Review on OHRP sign up now at www.wallstequities.com/registration . For today, WallStEquities.com observes Auris Medical Holding AG (NASDAQ: EARS), NewLink Genetics Corp. (NA...
Source: ACCESSWIRE IA
Date: July, 13 2018 07:40

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-180.410.38250.41050.37891,018,915
2018-12-170.43050.4150.450.415701,941
2018-12-140.4620.4290.4690.42937,292
2018-12-130.460.45970.47910.441,323,221
2018-12-120.460.45980.470.4112,564,416

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1883,503264,44131.5772Cover
2018-12-1721,59499,02621.8064Cover
2018-12-1495,922309,44630.9980Cover
2018-12-13190,435322,95358.9668Short
2018-12-12381,120577,20466.0286Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EARS.


About Auris Medical Holding AG (NASDAQ: EARS)

Logo for Auris Medical Holding AG (NASDAQ: EARS)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: EARS)

      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: May, 17 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 15 2018
      Prospectus filed under Rule 424(b)(3)
      Filing Type: 424B3Filing Source: edgar
      Filing Date: May, 15 2018
      Prospectus filed under Rule 424(b)(3)
      Filing Type: 424B3Filing Source: edgar
      Filing Date: May, 11 2018
      Registration statement for certain foreign private issuers
      Filing Type: F-1Filing Source: edgar
      Filing Date: May, 11 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 02 2018
      Withdrawal of registration statement filed under the Securities Act
      Filing Type: RWFiling Source: edgar
      Filing Date: April, 27 2018
      This filing is a pre-effective amendment to an F-1 filing
      Filing Type: F-1/AFiling Source: edgar
      Filing Date: April, 27 2018
      Amendment to a SC 13D filing
      Filing Type: SC 13D/AFiling Source: edgar
      Filing Date: April, 23 2018
      Filing by person(s) reporting owned shares of common stock in a public company >5%
      Filing Type: SC 13DFiling Source: edgar
      Filing Date: April, 03 2018

       

       


      Daily Technical Chart for (NASDAQ: EARS)

      Daily Technical Chart for (NASDAQ: EARS)


      Stay tuned for daily updates and more on (NASDAQ: EARS)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: EARS)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EARS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of EARS and does not buy, sell, or trade any shares of EARS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/